Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Givaudan seeks stevia flavor patents

This article was originally published in The Tan Sheet

Executive Summary

The Swiss flavor and fragrance firm applies to patent its advancements in blocking the bitter taste receptor that rebaudioside A triggers. Givaudan's flavor-masking technology "enhances the overall taste performance ... while reducing or eliminating the inherent sensory defects," the company says Feb. 12. Givaudan has more than 20 flavor ingredients that work against rebaudioside A's bitterness. Rebaudioside A sweeteners have been available in the U.S. since December 2008, but industry observers question whether consumers will accept stevia's aftertaste in certain food and beverage applications (1"The Tan Sheet" Dec. 22, 2008, p. 8)

You may also be interested in...



Stevia Products Roll Out As GRAS, But Must Win Over Consumer Sweet Tooth

Stevia-based sweeteners are enjoying a coming out party with FDA giving the go-ahead to Cargill's Truvia and Merisant's PureVia

‘Clear’ Is In The Eye Of The Beholder, New York, CRN Argue In Age-Restricted Sales Litigation

CRN’s request for clarification, as it continues litigating complaint in US District Court for Southern New York, highlights what it contends is vague and overly general language in the legislation passed in October with a 22 April effective date.

Biogen Sees Improving Momentum In Slow Leqembi Launch

Sales of the company’s new drugs have a lot of growing to do to make up for older products’ declines, but Biogen highlighted signs of strength for new launches in its Q1 report.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS102634

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel